科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background/purpose: beta-Tricalcium phosphate (beta-TCP) is an osteoconductive material which has been used for clinical purposes for several years, as is polycaprolactone (PCL), which has already been approved for a number of medical and drug delivery devices. In this study we have incorporated various concentrations of beta-TCP into PCL with the aim of developing an injectable, mechanically strong, and biodegradable material which can be used for medical purposes without organic solvents. Materials and methods: This study assesses the physical and chemical properties of this material, evaluates the in vitro bioactivity of the PCL/beta-TCP composites, and analyzes cell proliferation and osteogenic differentiation when using human bone marrow mesenchymal stem cells (hBMSCs). Results: The results show that weight losses of approximately 5.3%, 12.1%, 18.6%, and 25.2%, were observed for the TCPO, TCP10, TCP30, and TCP50 composites after immersion in simulated body fluid for 12 weeks, respectively, indicating significant differences (P < 0.05). In addition, PCL/beta-TCP composites tend to have lower contact angles (47 +/- 1.5 degrees and 58 +/- 1.7 degrees for TCP50 and TCP30, respectively) than pure PCL (85 +/- 1.3 degrees), which are generally more hydrophilic. After 7 days, a significant (22% and 34%, respectively) increase (P < 0.05) in alkaline phosphatase level was measured for TCP30 and TCP50 in comparison with the pure PCL. Conclusion: PCL/TCP is biocompatible with hBMSCs. It not only promotes proliferation of hBMSCs but also helps to differentiate reparative hard tissue. We suggest 50% (weight) PCLcontaining beta-TCP biocomposites as the best choice for hard tissue repair applications.
- 出版日期2017-3
- 单位中国医科大学
